Flu, COVID-19, RSV vaccines; Wisconsin residents urged to receive
Wisconsin Department of Health Services (DHS) data show only 17% of Wisconsinites have received a flu shot this season, and ...
中国日报网1d
First bivalent mRNA vaccine candidate against RSV goes under clinical trial
The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...
Pharmabiz14d
Clover announces positive clinical data for RSV vaccine candidate SCB-1019 compared head-to-head versus GSK’s Arexvy
trial evaluating SCB-1019 – the company's non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate based on Clover's Trimer-Tag vaccine technology platform – compared ...
malaymail15d
AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval
HONG KONG SAR - Media OutReach Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30 th October that mRNA respiratory syncytial virus (RSV) vaccine ...
Yahoo Finance15d
GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand
(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...
STAT15d
Sales of GSK’s RSV vaccine down dramatically from last year
Notably, quarterly sales of the company’s RSV vaccine, which became a blockbuster after debuting last year, fell by more than 70% year over year, in part due to narrower U.S. recommendations for ...
MedPage Today15d
RSV Vaccine 90% Effective in High-Risk Adults, Real-World Study Shows
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...
Yahoo Finance15d
GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand
(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...